How Much Upside is Left in Rapt Therapeutics (RAPT)? Wall Street Analysts Think 116%Zacks Investment Research • 11/17/22
Here's Why Rapt Therapeutics (RAPT) Looks Ripe for Bottom FishingZacks Investment Research • 09/23/22
How Much Upside is Left in Rapt Therapeutics (RAPT)? Wall Street Analysts Think 74%Zacks Investment Research • 09/01/22
Can Rapt Therapeutics (RAPT) Climb 59% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 08/16/22
This Mid-Cap Firm Can Potentially Offer Biggest Oral Drug In Atopic Dermatitis, Cantor Thinks SoBenzinga • 05/25/22
RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic DermatitisGlobeNewsWire • 05/23/22
RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial of RPT193 Consistent with Disease Modification in Atopic DermatitisGlobeNewsWire • 03/28/22
RAPT Therapeutics to Participate in the 11th Annual SVB Leerink Healthcare ConferenceGlobeNewsWire • 02/09/22
RAPT Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/22
RAPT Therapeutics Appoints Industry Veteran Lori Lyons-Williams to its Board of DirectorsGlobeNewsWire • 11/09/21
Rapt Therapeutics (RAPT) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 11/08/21
RAPT Therapeutics Announces Upcoming Oral Presentation of RPT193 Phase 1b Data at the 4th Inflammatory Skin Disease SummitGlobeNewsWire • 10/18/21